Teva Pharmaceutical Industries Ltd. was hit with a temporary restraining order by the U.S. District Court for the District of Northern Illinois that prevented the company from introducing its clarithromycin extended-release tablets (500 mg) pending the outcome of a preliminary injunction hearing that was scheduled for May 26. Teva's clarithromycin extended-release tablets are the AB-rated generic equivalent of Abbott's macrolide antibiotic Biaxin XL Filmtabs. The brand product has annual sales of approximately $284 million. Teva also received final approval for its ANDA for fenofibrate tablets, 54 mg and 160 mg, the AB-rated generic equivalent of Abbott's Tricor tablets indicated for the treatment of hypercholesterolemia and hypertriglyceridemia.
COPYRIGHT 2005 Reproduced with permission of the copyright holder. Further reproduction or distribution is prohibited without permission.
COPYRIGHT 2005 Gale Group
Contact
Home
A
Oxytetracycline